TAK-418
Based on 2 publication(s) in Google Scholar
TAK-418 is an orally active, blood-brain barrier-penetrant LSD1 inhibitor with a human IC50 of 2.9 nM. TAK-418 irreversibly inhibits LSD1 by forming a compact flavin-FAD adduct with the catalytic domain FAD, blocking the demethylation of H3K4me1/2 and H3K9me1/2 without disrupting the LSD1-GFI1B interaction. TAK-418 restores normally dysregulated brain gene expression and DNA methylation, increases H3K4me1/2/3 and H3K9me2 at the Ucp2 locus, and induces Ucp2 mRNA expression. TAK-418 rescues defective H3K4 histone modifications, normalizes adult neurogenesis, and improves recognition memory, social behavior, and cognition in rodent models. TAK-418 can be used in research related to neurodevelopmental disorders, Alzheimer's disease, and autism spectrum disorders.
For research use only. We do not sell to patients.
- Purity : 99.81%
- CAS No.: 1818252-53-7
- Formula: C17H25ClN2O2S
- Molecular Weight:356.91
-
Storage:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-100546A
GSK-LSD1 dihydrochlorideLSD1 Inhibitor -
HY-129388B
Pulrodemstat benzenesulfonateLSD1 Inhititor -
HY-100421
CPI-455KDM5 Inhibitor -
HY-122635A
T-448LSD1 Inhibitor -
HY-12304
IOX12OG Oxygenases Inhibitor -
HY-13643
DaminozideKDM2/7 Inhibitor -
HY-15648F
GSK-J4 hydrochlorideJMJD3/UTX Inhibitor -
HY-112623
VafidemstatLSD1 Inhibitor -
HY-104048
QC6352KDM4 Inhibitor -
HY-103713
SeclidemstatLSD1 Inhibitor -
HY-102047B
KDOAM-25 citrateKDM5 Inhibitor -
HY-120400
KDM5-C70KDM5 Inhibitor
Publications Citing Use of MedChemExpress (MCE) TAK-418
More
Biological Activity
Description
IC50 & Target
[2]|
LSD1 2.9 nM (IC50) |
In Vitro
TAK-418 (10 μM; 1 h) engages its cellular target LSD1 in TF-1a cells, as demonstrated by increased thermal stability of the protein[1].
TAK-418 (free base) is a specific inhibitor of LSD1 enzyme activity with an IC50 of 2.9 nM[2].
TAK-418 (free base) (40 min) inhibits LSD1 demethylase activity in the HTRF-based assay[2].
TAK-418 (free base) (1 or 3 days) increases histone methylation at the Ucp2 gene in primary cultured rat neurons[2].
TAK-418 (free base) (1 or 3 days) increases histone methylation at the Bdnf gene in primary cultured rat neurons[2].
TAK-418 (free base) (3 days) induces Ucp2 mRNA expression in primary cultured rat neurons[2].
TAK-418 (free base) has minimal impact on the LSD1-GFI1B interaction in TF-1a cells[2].
TAK-418 (free base) (1 mM; 1 h) forms a compact formylated FAD adduct in LSD1 protein[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:primary cultured rat neurons
-
Concentration:0.0001, 0.001, 0.01, 0.1, 1 and 10 μM
-
Incubation Time:3 days
-
Result:Increased H3K4me2 and H3K9me2 at the Ucp2 gene and induced Ucp2 mRNA expression.
Increased H3K4me1/2/3 at the Bdnf gene.
In Vivo
TAK-418 (1 mg/kg; p.o.; once daily; 14 days) does not improve memory, sociability, or sensorimotor gating deficits in miR-137 Tg mice[1].
TAK-418 (1 mg/kg; p.o.; once daily; 14 days) restores dysregulated gene expression and DNA methylation, and ameliorates social deficits and cognitive impairment in VPA (HY-10585)-induced ASD model rats[2].
TAK-418 (0.1-1 mg/kg; p.o.; once daily; 14 days) improves social behavior in poly I:C (HY-107202)-induced ASD model mice and restores dysregulated gene expression and DNA methylation to normal levels[2].
TAK-418 (1 mg/kg; p.o.; single administration or once daily for 14 days) does not affect cognitive function in normal healthy rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (aged male, 11-14 months old at purchase; 16 months old at testing)[1]
-
Dosage:0.1 or 0.3 mg/kg
-
Administration:p.o.; once daily; 4 days
-
Result:Improved recognition memory in aged mice, as assessed by the NOR test.
-
Animal Model:Tg2576 (female, 9 months old)[1]
-
Dosage:0.1 or 0.3 mg/kg
-
Administration:p.o.; once daily; 4 days
-
Result:Improved recognition memory deficits in Tg2576 mice at 0.3 mg/kg.
-
Animal Model:miR-137 transgenic (4 months old)[1]
-
Dosage:1 mg/kg
-
Administration:p.o.; once daily; 14 days
-
Result:Did not improve memory function in miR-137 Tg mice, as assessed by NOR tests.
Did not rescue sociability deficits or sensorimotor gating abnormalities.
-
Animal Model:Sprague-Dawley (SD) (male, juvenile and adult, maternal VPA exposure)[2]
-
Dosage:1 mg/kg
-
Administration:p.o.; once daily; 14 days (sociability, repetitive behavior, RNA-seq, ChIP-seq, RRBS); single administration (sociability); 1 week (sociability); 16-20 days (cognition)
-
Result:Showed 95.7% inhibition of LSD1 enzyme activity.
Completely recovered sociability in juvenile VPA rats at 1 mg/kg.
Completely recovered sociability in adult VPA rats at 1 mg/kg.
Recovered sociability in juvenile VPA rats after 1-week QD administration.
Significantly rescued decreased novelty discrimination index (NDI) in 6-week-old VPA rats after 16-20 days QD administration.
Observed inverse correlation between disease-induced changes and TAK-418 effects with correlation coefficients of -0.912 (juvenile) and -0.928 (adult).
Normalized dysregulated patterns of H3K9ac (correlation coefficient = -0.75) and DNA methylation (correlation coefficient = -0.90).
-
Animal Model:C57BL/6J (male, adult, maternal poly I:C exposure)[2]
-
Dosage:0.1-1 mg/kg
-
Administration:p.o.; QD; 14 days
-
Result:Showed 91.5% inhibition of LSD1 enzyme activity.
Significantly increased the sniffing index at 0.1, 0.3, or 1 mg/kg.
Observed inverse correlation between disease-induced changes and TAK-418 effects with a correlation coefficient of -0.958.
Normalized dysregulated patterns of DNA methylation with a correlation coefficient of -0.96.
-
Animal Model:Long-Evans (male, 7-week-old, naive)[2]
-
Dosage:1 mg/kg
-
Administration:p.o.; single administration or QD; 14 days
-
Result:Had no effects on delay-dependent forgetting of object memory.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1818252-53-7
-
Appearance Solid-Liquid Mixture
-
Molecular Weight 356.91
-
Formula C17H25ClN2O2S
-
Color White to yellow
-
SMILES
O=C(C1=CSC([C@H]2[C@H](NCC3CC3)C2)=C1)NC4CCOCC4.[H]Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nature
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation. [Abstract]2025 Jun;642(8067):508-518. PMID: 40240608 -
Proc Natl Acad Sci U S A
2025 May 20;122(20):e2425812122. PMID: 40366693
Solvent & Solubility
In Vitro:
DMSO : 55 mg/mL (154.10 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 16.67 mg/mL (46.71 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5.5 mg/mL (15.41 mM); Clear solution
This protocol yields a clear solution of ≥ 5.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (55.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5.5 mg/mL (15.41 mM); Clear solution
This protocol yields a clear solution of ≥ 5.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (55.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocols
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Epigenomic Data Analysis
Epigenomic data analysis identifies genome-wide regulatory features that influence gene expression, chromatin state, and phenotype without changing the underlying DNA sequence. In this strategy, the core regulatory layer includes chromatin accessibility, transcription-factor or histone-mark occupancy, DNA methylation, and chromatin-state patterns; these features are measured by sequencing-based assays and interpreted as regulatory elements, promoters, enhancers, repressive domains, methylated cytosines, or candidate phenotype-associated chromatin programs. The literature links epigenomic features to phenotype by showing that functional genomic elements can be mapped across human cell types and tissues, and that integrated epigenomic maps reveal cell-type-specific regulatory programs. ENCODE integrated transcription, chromatin accessibility, transcription-factor occupancy, and histone modification data to annotate functional elements in the human genome, while the Roadmap Epigenomics Co
-
SH-SY5Y neuronal-like differentiation
SH-SY5Y neuronal-like differentiation uses defined culture conditions to shift proliferative human neuroblastoma cells toward a neuron-like state, mainly assessed by reduced proliferation, neurite extension, neuronal-marker expression, and, in some protocols, increased dependence on neurotrophic support. Retinoic acid (RA) is commonly used for the first differentiation phase, and sequential RA followed by brain-derived neurotrophic factor (BDNF) in serum-free medium is a well-characterized approach for generating neuron-like SH-SY5Y cultures with extensive neurite outgrowth. The primary readouts are morphology-based neurite outgrowth and marker-based confirmation using proteins such as βIII-tubulin, MAP2, GAP43, synaptophysin, NeuN, NSE, TH, or related neuronal/synaptic markers, depending on the study endpoint.
-
Cell differentiation
Cell differentiation refers to the process in which cells of the same origin gradually produce cell groups with different morphological structure and functional characteristics.
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
-
Data Sheet (292 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.8018 mL | 14.0091 mL | 28.0183 mL | 70.0457 mL |
| 5 mM | 0.5604 mL | 2.8018 mL | 5.6037 mL | 14.0091 mL | |
| 10 mM | 0.2802 mL | 1.4009 mL | 2.8018 mL | 7.0046 mL | |
| 15 mM | 0.1868 mL | 0.9339 mL | 1.8679 mL | 4.6697 mL | |
| 20 mM | 0.1401 mL | 0.7005 mL | 1.4009 mL | 3.5023 mL | |
| 25 mM | 0.1121 mL | 0.5604 mL | 1.1207 mL | 2.8018 mL | |
| 30 mM | 0.0934 mL | 0.4670 mL | 0.9339 mL | 2.3349 mL | |
| 40 mM | 0.0700 mL | 0.3502 mL | 0.7005 mL | 1.7511 mL | |
| DMSO | 50 mM | 0.0560 mL | 0.2802 mL | 0.5604 mL | 1.4009 mL |
| 60 mM | 0.0467 mL | 0.2335 mL | 0.4670 mL | 1.1674 mL | |
| 80 mM | 0.0350 mL | 0.1751 mL | 0.3502 mL | 0.8756 mL | |
| 100 mM | 0.0280 mL | 0.1401 mL | 0.2802 mL | 0.7005 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
TAK-418 Related Classifications
HY-138830 Related Classifications
Powered by Bioz